연구성과로 돌아가기

2025 연구자 정보 (363 / 657)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Bang, Soo-Mee
(Bang, SM)
Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Coll Med, Seongnam, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Cheong, June-Won
(Cheong, JW)
Yonsei Univ, Coll Med, Severance Hosp,Dept Internal Med, Div Hematol, Seoul, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Choi, Chul Won
(Choi, CW)
Korea Univ, Guro Hosp, Div Oncol & Hematol, Dept Internal Med, Seoul, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Choi, Eun-Ji
(Choi, EJ)
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Lee, Gyeong-Won
(Lee, GW)
Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp,Inst Hlth Sci, Div Hematol & Oncol,Dept Internal Med, Jinju, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Oh, Suk Joong
(Oh, SJ)
Hanyang Univ, Dept Oncol, Asan Med Ctr, Seoul 138736, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Park, Joon Seong
(Park, JS)
Ajou Univ, Sch Med, Dept Hematol Oncol, Suwon, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Park, Yong
(Park, Y)
Korea Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Park, Young Hoon
(Park, YH)
Ewha Womans Univ, Mokdong Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea
MBG-1896-2025
Park, Young Sik

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
[JCR상위 36.2] Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (vol 60, 9, 2025)
SCIE
ESCI
23.5 ONCOLOGY
HEMATOLOGY
lee86@catholic.ac.kr;
kihyunkimk@gmail.com;
Yoon, Seug Yun
(Yoon, SY)
제1저자 Soonchunhyang Univ, Seoul Hosp, Dept Internal Med, Div Hematol & Med Oncol, Seoul, South Korea

[JCR상위 23.5] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study SCIE 23.5 ONCOLOGY lee86@catholic.ac.kr;
Choi, Keum-Ju
(Choi, KJ)
Daegu Catholic Univ, Coll Med, Dept Internal Med, Daegu, South Korea

[JCR상위 23.6] Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy SCIE 23.6 ONCOLOGY;RESPIRATORY SYSTEM fireajh@gmail.com;
Hong, Kyung Soo
(Hong, KS)
Yeungnam Univ, Coll Med, Dept Internal Med, 170 Hyeonchung Ro, Daegu 42415, South Korea

[JCR상위 23.6] Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy SCIE 23.6 ONCOLOGY;RESPIRATORY SYSTEM fireajh@gmail.com;
Jang, Jong Geol
(Jang, JG)
Yeungnam Univ, Coll Med, Dept Internal Med, 170 Hyeonchung Ro, Daegu 42415, South Korea

[JCR상위 23.6] Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy SCIE 23.6 ONCOLOGY;RESPIRATORY SYSTEM fireajh@gmail.com;
Kim, Chanmi
(Kim, C)
Yonsei Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
Yeungnam Univ, Coll Med, Dept Internal Med, 170 Hyeonchung Ro, Daegu 42415, South Korea


[JCR상위 23.6] Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy SCIE 23.6 ONCOLOGY;RESPIRATORY SYSTEM fireajh@gmail.com;
Kim, Jehun
(Kim, J)
Kosin Univ, Coll Med, Dept Internal Med, Busan, South Korea

[JCR상위 23.6] Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy SCIE 23.6 ONCOLOGY;RESPIRATORY SYSTEM fireajh@gmail.com;
페이지 이동: